These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34592178)

  • 1. An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.
    Hackshaw A; Berg CD
    Lancet Oncol; 2021 Oct; 22(10):1360-1362. PubMed ID: 34592178
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: All-cause mortality in randomized trials of cancer screening.
    Weiss NS; Koepsell TD
    J Natl Cancer Inst; 2002 Jun; 94(11):864-5; author reply 865-6. PubMed ID: 12048281
    [No Abstract]   [Full Text] [Related]  

  • 3. Design of cancer screening trials/randomized trials for evaluation of cancer screening.
    Miller AB
    World J Surg; 2006 Jul; 30(7):1152-62. PubMed ID: 16794902
    [No Abstract]   [Full Text] [Related]  

  • 4. Should we expect all-cause mortality reductions in large screening studies?
    Dobbin KK; Ebell M
    Br J Gen Pract; 2018 Jun; 68(671):290-291. PubMed ID: 29853594
    [No Abstract]   [Full Text] [Related]  

  • 5. The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening.
    Dhruva SS; Smith-Bindman R; Redberg RF
    JAMA Intern Med; 2023 Oct; 183(10):1051-1053. PubMed ID: 37639263
    [No Abstract]   [Full Text] [Related]  

  • 6. Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects.
    Liu MC
    Br J Cancer; 2021 Apr; 124(9):1475-1477. PubMed ID: 33558712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer screening: evidence and practice in Europe 2008.
    Hakama M; Coleman MP; Alexe DM; Auvinen A
    Eur J Cancer; 2008 Jul; 44(10):1404-13. PubMed ID: 18343653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-cause mortality in randomized trials of cancer screening.
    Black WC; Haggstrom DA; Welch HG
    J Natl Cancer Inst; 2002 Feb; 94(3):167-73. PubMed ID: 11830606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials.
    Saquib N; Saquib J; Ioannidis JP
    Int J Epidemiol; 2015 Feb; 44(1):264-77. PubMed ID: 25596211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer DNA blood test gets real-world trial.
    Kaiser J
    Science; 2020 May; 368(6490):461. PubMed ID: 32355013
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: All-cause mortality in randomized trials of cancer screening.
    Gail MH; Katki HA
    J Natl Cancer Inst; 2002 Jun; 94(11):862; author reply 865-6. PubMed ID: 12048278
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
    Robertson L; Yeoh SE; Broderick C; Stansby G; Agarwal R
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010837. PubMed ID: 30407621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study designs for determining and comparing sensitivities of disease screening tests.
    Prorok PC; Kramer BS; Miller AB
    J Med Screen; 2015 Dec; 22(4):213-20. PubMed ID: 26396138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
    Robertson L; Yeoh SE; Stansby G; Agarwal R
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design issues in cancer screening trials.
    Moss S
    Stat Methods Med Res; 2010 Oct; 19(5):451-61. PubMed ID: 20442197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic approach for cancer screening. Problems in design and analysis of trials.
    Prorok PC
    Am J Pediatr Hematol Oncol; 1992 May; 14(2):117-28. PubMed ID: 1530116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parachutes, randomized controlled trials, and all-cause mortality.
    Milovac T
    Hist Philos Life Sci; 2022 Nov; 44(4):68. PubMed ID: 36434291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
    Owens L; Gulati R; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1298-1304. PubMed ID: 35477176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
    Mian BM
    Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
    [No Abstract]   [Full Text] [Related]  

  • 20. The cancer genome and diagnostic blood tests.
    Lance P
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2017-8. PubMed ID: 17119024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.